When the people who know a company best are selling, it's worth paying attention. Three Nvidia executives have dumped over $105 million in stock since January 1st, and four billionaire fund managers just disclosed massive position cuts — all ahead of Wednesday's Q4 earnings report. CFO Colette Kress led the insider parade, unloading multiple batches across January and February totaling nearly $17 million. Executive VP Ajay Puri offloaded 400,000 shares worth roughly $73 million. Donald Robertson sold another 80,000 shares on New Year's Day. Across the board, Nvidia insiders have sold approxim...

Novo Nordisk had one job: prove its next-generation obesity drug could go toe-to-toe with Eli Lilly's juggernaut. It couldn't. Results from the Redefine 4 trial, released Monday morning, showed that Novo's CagriSema — a combination of semaglutide and cagrilintide — produced less weight loss than Eli Lilly's tirzepatide, sold as Zepbound for obesity and Mounjaro for Type 2 diabetes. Novo shares tanked 8.4% in premarket trading, adding to what's been a brutal stretch for the Danish pharma giant. This isn't just a clinical setback. It's a strategic one. CagriSema was supposed to be Novo's answe...

The biggest rotation in 16 years is happening and most retail investors are sleeping through it. U.S.-domiciled investors have yanked $75 billion from American equity products in the last six months — with $52 billion of that flowing out since January alone. That's the fastest exit in the first eight weeks of any year since at least 2010, according to LSEG/Lipper data. Where's the money going? Emerging markets sucked up $26 billion so far this year, with South Korea ($2.8 billion), Brazil ($1.2 billion), and Europe leading the charge. Bank of America's February fund manager survey showed the...

Well, well, well. Look who decided to show up to the 6,000 party again. The S&P 500 just closed at exactly 6,000 on Friday, and honestly, it feels like watching your friend finally get their life together after a really messy breakup with economic uncertainty. This is the first time we've seen this level since February, which in market years feels like approximately seventeen lifetimes ago. Between then and now, we've had tariff tantrums, inflation anxiety, and enough economic drama to fuel a Netflix series. The index took a 15% nosedive earlier this year, bottoming out around 4,983 in April....

Remember when your friend dropped $36,000 on a tiny Hermès bag and you thought they'd lost their mind? Plot twist: they might be the smartest investor you know. While you've been stress-watching your tech stocks do the cha-cha, luxury handbags have been quietly demolishing the S&P 500 like it's amateur hour. We're talking about the Mini Kelly II handbag returning over 300% from 2022 to 2025, starting at $9,200 and climbing to $36,980. Meanwhile, the S&P 500 managed a respectable but comparatively wimpy 43%. The iconic Birkin wasn't slacking either, appreciating 285% in the same period. That'...

Remember when your friend dropped $36,000 on a tiny Hermès bag and you thought they'd lost their mind? Well, plot twist: they might be the smartest investor you know. While you've been obsessing over AI stocks and checking your portfolio every five minutes, luxury handbags have been quietly demolishing the S&P 500. And we're not talking about a small win here – we're talking about a complete beatdown that would make even the most aggressive day trader weep. The star of this financial fairy tale? The Hermès Mini Kelly II, which sounds like a fancy coffee drink but performs like a hedge fund o...

While you've been obsessing over whether to buy more NVIDIA or finally diversify into something boring like bonds, there's been a quiet revolution happening in the world of luxury accessories. And no, I'm not talking about crypto wallets—I'm talking about actual wallets. Well, handbags. Really expensive handbags. Here's the plot twist that would make even the most seasoned Wall Street trader do a double-take: Hermès bags have been absolutely demolishing the stock market. We're talking about purses that cost more than most people's cars outperforming your carefully curated portfolio of tech st...

The Strait of Hormuz. Three words that should be on every trader's watchlist this week. President Trump signaled Thursday that he'll decide within ten days whether to launch strikes against Iran. The U.S. military has deployed the USS Abraham Lincoln carrier group within striking distance. Vice President JD Vance says "certain red lines" remain in nuclear talks. And Iran's Revolutionary Guard has already partially closed the strait for military exercises — a flex that sent oil prices up 5% on the week to their highest level in six months. Here's what the market is — and isn't — pricing in. ...

There's a paradox unfolding in precious metals that should have every value investor paying attention. Gold has shattered $5,000 per ounce. Silver blew through $100 and is trading near $110. Yet the companies that pull these metals out of the ground are trading at a 15% to 17% discount to the underlying bullion. This valuation gap is the kind of setup that legendary investors dream about — and it's already starting to close. The numbers tell the story. All-In Sustaining Costs for senior gold producers have leveled off around $1,800 per ounce, while gold trades at nearly triple that cost. Tha...

Grail just learned what happens when the most anticipated clinical trial in cancer diagnostics misses its mark. The stock lost nearly half its value on Friday. The company's Galleri blood test — designed to detect multiple types of cancer from a simple blood draw — was supposed to be the future of early screening. England's National Health Service ran a three-year trial involving 142,000 participants to test whether adding Galleri to standard screening could shift cancer diagnoses to earlier, more treatable stages. The primary endpoint: a statistically significant reduction in Stage III and I...